Vivos Therapeutics Inc
NASDAQ:VVOS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
13.7m USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
101.2B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
64.9B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
77.2B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
28.8B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.3B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.7B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
23.4B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.4B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.3B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.7B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Vivos Therapeutics Inc
Glance View
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Vivos Therapeutics Inc is 55.7%, which is below its 3-year median of 59.2%.
Over the last 3 years, Vivos Therapeutics Inc’s Gross Margin has decreased from 65.3% to 55.7%. During this period, it reached a low of 55.7% on Sep 30, 2025 and a high of 65.3% on Sep 30, 2022.
